Iron Sucrose

# Iron sucrose ## Overview - **Classification**: Iron replacement product, parenteral iron - **Mechanism**: Replenishes body iron stores. Iron is delivered to erythroid progenitor cells in bone marrow for hemoglobin synthesis. ## Primary Indications 1. **Iron Deficiency Anemia (IDA) in CKD**: Patients on hemodialysis receiving erythropoietin-stimulating agents (ESAs). 2. **IDA in Non-dialysis Dependent CKD**: Patients on ESAs or not on ESAs. 3. **IDA in Adult Patients**: When oral iron is ineffective or cannot be tolerated. ## Adult Dosing ### Standard Dosing **IDA in Hemodialysis-Dependent CKD (on ESAs)** - **Dose**: **100 mg** - **Frequency**: Administered during sequential dialysis sessions - **Route**: IV bolus or slow IV infusion - **Duration**: Total cumulative dose of **1000 mg** over 10 sequential dialysis sessions **IDA in Non-Dialysis Dependent CKD (on ESAs or not)** - **Dose**: **200 mg** - **Frequency**: Administered on 5 different occasions over 14-day period. - **Route**: IV infusion over at least 15 minutes. - **Total cumulative dose**: **1000 mg**. - **Alternatively (rapid repletion)**: **300 mg** IV over 1.5 hrs on Day 1, **300 mg** IV over 1.5 hrs on Day 8, **400 mg** IV over 2.5 hrs on Day 15. Total **1000 mg**. **IDA in Adult Patients (when oral iron ineffective/intolerable)** - **Dose**: **200 mg** - **Frequency**: Repeated 5 times over 14 days for a total of **1000 mg**. - **Route**: IV infusion over at least 15 minutes. - **Alternatively (rapid repletion)**: **500 mg** diluted in 250 mL NS and infused over 3.5-4 hours once a week for 2 doses (total **1000 mg**). ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment needed; indication is for CKD. - **Hepatic Impairment**: No specific dose adjustment guidance. Use with caution. - **Elderly Patients**: No specific dose adjustment needed. Start with lowest dose and monitor closely. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Safety and efficacy **not established**. - **Special Notes**: Use only if potential benefit clearly outweighs risks. Close monitoring required. ### Infants (1-12 months) - **Dose**: Safety and efficacy **not established**. - **Special Notes**: Limited data. Not routinely recommended for IDA. ### Children (1-12 years) - **Indication**: IDA in CKD (dialysis-dependent and non-dialysis dependent) on ESAs. - **Dose**: **0.5 mg/kg** to **3.5 mg/kg** per dose. - **Frequency**: Up to 3 times per week, during sequential dialysis sessions (for dialysis patients). - **Maximum**: **100 mg** per single dose. - **Total cumulative dose**: Typically **500 mg** or **1000 mg** depending on iron deficit. - **Special Notes**: Infuse slowly. Closely monitor for hypersensitivity reactions. ### Adolescents (13-18 years) - **Indication**: IDA in CKD (dialysis-dependent and non-dialysis dependent) on ESAs; or when oral iron is ineffective/intolerable. - **Dose**: Follow adult dosing guidelines. - **Maximum**: Adult maximum doses apply (e.g., **200 mg** per single dose, cumulative **1000 mg**). - **Special Notes**: Ensure appropriate weight-based dosing if body weight is significantly lower than average adult. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to iron sucrose or any excipient. - **Absolute**: Anemia not caused by iron deficiency. - **Absolute**: Iron overload (e.g., hemochromatosis, hemosiderosis). ### Common Adverse Effects - **Very Common (>10%)**: Hypotension, headache. - **Common (1-10%)**: Nausea, vomiting, diarrhea, constipation, dizziness, peripheral edema, injection site reactions, hypertension, muscle cramps, dyspnea. - **Serious but Rare**: Anaphylactoid reactions, severe hypotension, loss of consciousness, arrhythmias, bronchospasm, cardiovascular collapse. ### Key Drug Interactions - **Oral Iron Supplements**: IV iron may reduce absorption of oral iron. - **Clinical Significance**: Do not administer oral iron within 24 hours of IV iron sucrose. - **ACE Inhibitors**: May enhance hypersensitivity reactions with IV iron. - **Monitoring**: Observe for increased risk of anaphylaxis. ## Monitoring & Follow-up - **Before Treatment**: - **Iron Status**: Serum ferritin, Transferrin Saturation (TSAT), CBC (hemoglobin, hematocrit). - **Hypersensitivity History**: Assess for prior reactions to parenteral iron. - **During Treatment**: - **Hypersensitivity**: Monitor vital signs closely during and for at least **30 minutes** post-infusion. - **Iron Status**: Re-evaluate iron parameters (ferritin, TSAT, Hb) **at least 4 weeks** after the last dose. - **Injection Site**: Monitor for extravasation. - **Clinical Signs**: - Watch for signs of allergic reaction (rash, dyspnea, hypotension). - Monitor for dizziness, headache, GI upset. ## Clinical Pearls - 💡 **Test Dose**: A test dose is **not recommended** as it does not reliably predict serious hypersensitivity reactions. - 💡 **Infusion Rate**: Administer as a **slow IV infusion** to minimize risk of hypotension and infusion-related reactions. - 💡 **Extravasation**: If extravasation occurs, discontinue infusion immediately; apply warm compress. - 💡 **Oral Iron**: Discontinue oral iron before starting iron sucrose to prevent iron overload. - 💡 **Formulation**: Compatible only with **0.9% Sodium Chloride (Normal Saline)** for dilution. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.